10-Q: Quince Therapeutics Reports Q2 2024 Results, Highlights Progress in EryDex Clinical Trial

Quince Therapeutics reported its second quarter 2024 results, including a significant goodwill impairment charge, while also highlighting progress in its Phase 3 clinical trial for EryDex.

Summary

• Quince Therapeutics reported a net loss of $27.7 million for the three months ended June 30, 2024, and a net loss of $38.9 million for the six months ended June 30, 2024.
• The company incurred a goodwill impairment charge of $17.1 million during the quarter.
• Research and development expenses increased to $4.1 million for the three months ended June 30, 2024, and $7.8 million for the six months ended June 30, 2024, primarily due to the start-up costs of the Phase 3 NEAT clinical trial for EryDex.
• General and administrative expenses were $4.7 million for the three months ended June 30, 2024, and $9.7 million for the six months ended June 30, 2024.
• The company's cash, cash equivalents, and short-term investments totaled $59.4 million as of June 30, 2024.
• Quince believes its existing capital resources will be sufficient to fund its planned operations for at least the next 12 months.
• The company enrolled the first patient in the Phase 3 NEAT clinical trial of EryDex in A-T during the second quarter of 2024 and expects to report topline results in the fourth quarter of 2025.
• The FDA granted Fast Track designation for the EryDex System for the treatment of patients with A-T.
• The company updated an initial patient sizing project with further third-party analysis from IQVIA Medical Claims (Dx), PharmetricsPlus (P+), and IQVIA Analytics, which confirmed that there are approximately 4,600 diagnosed patients with A-T in the U.S. as of July 2024.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While there is progress in the clinical trial and regulatory front, the significant goodwill impairment and increased losses raise concerns about the company's financial health. The need for potential future capital raises also adds to the uncertainty.

Positives

• The company successfully initiated the Phase 3 NEAT clinical trial for EryDex.
• The FDA granted Fast Track designation for EryDex, which may expedite the regulatory review process.
• The company has sufficient cash to fund operations for at least the next 12 months.
• The company updated patient sizing project with further third-party analysis confirming approximately 4,600 diagnosed patients with A-T in the U.S.

Negatives

• The company reported a significant net loss of $27.7 million for the three months ended June 30, 2024.
• A substantial goodwill impairment charge of $17.1 million was recorded, indicating a decrease in the value of acquired assets.
• The company's accumulated deficit has increased to $358.5 million as of June 30, 2024.
• The company has incurred losses and negative cash flows from operations since inception and expects to continue to generate operating losses for the foreseeable future.

Risks

• The company is substantially dependent on the success of EryDex, and the Phase 3 NEAT clinical trial may not be successful.
• The company has no approved drug candidates and may never be profitable.
• The company may be required to make milestone payments to EryDel shareholders and pursuant to the EIB Facility, which could adversely affect profitability.
• Clinical drug development is a lengthy, expensive, and uncertain process.
• The company may experience difficulties integrating Quince and EryDel's operations.
• The company may be unable to obtain and maintain sufficient intellectual property protection.
• The company may be unable to regain and maintain compliance with Nasdaq minimum listing requirements.

Future Outlook

The company expects to report topline results from the Phase 3 NEAT clinical trial in the fourth quarter of 2025 and plans to submit a U.S. NDA in 2026, assuming positive study results. The company also plans to initiate a DMD proof-of-concept study in 2025.

Management Comments

• Management believes that the company's existing capital resources will be sufficient to fund its planned operations for at least the next twelve months.
• Management expects to incur additional losses in the future to fund the company's operations and conduct product research and development and may need to raise additional capital to fully implement its business plan.

Industry Context

The company is focused on developing treatments for rare diseases, a sector with high unmet medical needs and significant commercial potential. The company's AIDE technology platform and EryDex drug candidate are positioned to address limitations of conventional therapies, particularly in the use of corticosteroids.

Comparison to Industry Standards

• The company's R&D expenses are typical for a clinical-stage biotech company focused on late-stage development, with a significant increase due to the Phase 3 trial.
• The goodwill impairment charge is a significant event, indicating a reevaluation of the company's assets following the EryDel acquisition, which is not uncommon in the biotech industry.
• The company's cash position is relatively low for a company in Phase 3 clinical trials, suggesting a potential need for additional financing in the near future.
• The company's focus on rare diseases aligns with a growing trend in the pharmaceutical industry, where there is increasing investment in treatments for orphan indications.
• The company's reliance on third-party manufacturers and CROs is standard practice in the biotech industry, but introduces risks related to supply chain and quality control.

Stakeholder Impact

• Shareholders may be concerned about the significant net loss and goodwill impairment charge.
• Employees may be affected by the company's cost reduction program and potential future changes in operations.
• Patients with A-T may benefit from the progress in the EryDex clinical trial and the Fast Track designation.
• Potential partners may be interested in the company's AIDE technology platform and EryDex drug candidate.

Next Steps

• Complete enrollment in the Phase 3 NEAT clinical trial in the first half of 2025.
• Report Phase 3 NEAT clinical trial top-line results in the fourth quarter of 2025.
• Prepare for a U.S. NDA submission in 2026, provided positive NEAT clinical trial results are obtained.
• Pursue potential strategic partnerships to out-license ex-U.S. regional territories.
• Initiate a DMD proof-of-concept study in 2025.

Key Dates

Keywords

EryDex, Ataxia-Telangiectasia, A-T, Clinical Trial, AIDE Technology, Biotechnology, Rare Disease, Phase 3, FDA Fast Track, Goodwill Impairment